Demant stock gains focus after strong Oticon Reveal quarter
Published on 11/11/2026 at 03:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSStrong quarter supports Demant outlook
- Demant reported 21 percent third-quarter revenue growth, with organic growth at 11 percent.
- Oticon Reveal drove 17 percent organic growth in external Hearing Aids revenue.
- Management reiterated 2026 organic growth guidance of 7 to 8 percent and resumed share buybacks.
Demant reported a strong third quarter on November 3, 2026, as revenue rose 21 percent year over year to DKK 6.624 billion. The company's Interim Management Statement, published through Nasdaq Copenhagen, showed organic group growth of 11 percent.
Oticon Reveal drives hearing aids
Hearing Aids was the main growth engine. External revenue in the business rose 17 percent organically to DKK 2.747 billion, supported by the launch of Oticon Reveal. Demant said the product accelerated the momentum created by Oticon Zeal and received a favorable response across markets and channels.
Hearing Care delivered 6 percent organic growth, while acquisitions, mainly the German retailer KIND, contributed to a 22 percent acquisitive increase in that business. Diagnostics grew 4 percent organically. Demant also said gross margin improved, helped by a higher average selling price in Hearing Aids and the KIND acquisition.
Guidance and capital returns
Demant reiterated its upgraded 2026 outlook for organic growth of 7 to 8 percent and EBIT before special items of DKK 4.7 billion to DKK 5.0 billion. The company expects the hearing aid market to grow 4 to 5 percent in value during 2026 and cited a competitive environment with several product launches in the second half.
Share buybacks have resumed in the fourth quarter. Demant expects to repurchase shares worth at least DKK 3 billion from the fourth quarter of 2026 through the end of 2027, while targeting a gearing multiple of 2.0 to 2.5 at the end of that period. The company also expects cost-effectiveness initiatives to support EBIT before special items by about DKK 300 million in 2026.
Demant's competitive position
Demant is a Denmark-headquartered hearing healthcare group offering hearing aids, hearing care, diagnostic equipment and related services. Its brands and solutions are present in 130 countries, and the group employs more than 26,000 people, according to its Q3 statement.
The global hearing-aid market is concentrated among Demant, Sonova, WS Audiology, GN Store Nord and Starkey, according to Counterpoint Research. Demant competes with these groups through Oticon-led hearing-aid innovation, hearing-care operations and diagnostics, while competitors emphasize alternative brands and technology platforms.
Demant at a glance
- Company: Demant A/S
- ISIN: DK0060738599
- Headquarters: Denmark
- Business: Hearing aids, hearing care, diagnostics and related services
- Latest reported period: Third quarter 2026
European equities remain a relevant backdrop for investors following Demant's Copenhagen listing. See Current market reports for the broader market environment.
